Asset Details
Do you wish to reserve the book?
Novel Long-Acting Crystal Formulation of Human Growth Hormone
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Novel Long-Acting Crystal Formulation of Human Growth Hormone
Do you wish to request the book?
Novel Long-Acting Crystal Formulation of Human Growth Hormone
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Novel Long-Acting Crystal Formulation of Human Growth Hormone
2005
Overview
The aim of the study is to solve a significant challenge of extending the half-life of therapeutic proteins using crystalline biopharmaceuticals and without redesigning the molecules.
Crystals of recombinant human growth hormone were coated with a monomolecular layer of positively charged poly(arginine). The pharmacokinetics and pharmacodynamics of this poly(arginine)-coated human growth hormone crystalline formulation were determined in hypophysectomized rats and monkeys.
Here we have demonstrated for the first time that crystals of human growth hormone coated with positively charged poly(arginine) allowed for in vivo pharmacokinetic release profiles of over several days in animal models. The efficacy of this crystalline formulation injected subcutaneously once a week was found to be equivalent to seven daily soluble injections in the standard weight gain assay using the hypophysectomized rat model and in measurement of serum insulin-like growth factor in monkeys. The nonviscous nature of the suspension facilitated easy administration through a fine, 30-gauge needle and should provide for improved patient convenience and compliance.
The approach described here offers an exciting possibility of being broadly applicable to other therapeutic proteins.
Publisher
Springer Nature B.V
Subject
/ Animals
/ Crystals
/ Female
/ Human Growth Hormone - chemistry
/ Human Growth Hormone - pharmacokinetics
/ Human Growth Hormone - pharmacology
/ Humans
/ Insulin
/ Liquor
/ Microscopy, Electron, Scanning
/ Proteins
/ Rats
/ Recombinant Proteins - chemistry
/ Recombinant Proteins - pharmacokinetics
/ Recombinant Proteins - pharmacology
/ Sodium
